BranchLab
New York, US · Founded 2024 · Delaware corporation · 51 employees on LinkedIn · 9 known investors
Branchlab offers an AI-driven platform for healthcare marketing that helps teams explore patient, HCP, and caregiver audiences without exposing Protected Health Information, then create, optimize, and activate those audiences across channels. It uses predictive modeling to target healthcare campaigns and measure real-world outcomes for marketers in the healthcare industry.
Also known as BranchLab Inc
Founders & leadership
Board
Investors · 9
Reported raises · per SEC filings
Form D private placements$28.8M disclosed across 1 of 2 rounds · 2024–2026
▶$28.8MraisedMay 2026 · 27 investors · Other TechnologyRule 506(b)
- Michael ParkesDirector
- Joshua WalshExecutive Officer, Director
- Carrie WilliamsDirector
- Andrew BouldinDirector
- Offering amount
- $28.8M
- Amount sold
- $28.8M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedApr 2024 · Other TechnologyRule 506(b)
- Joshua WalshExecutive Officer, Director
- Christopher CagleExecutive Officer, Director
- Michael ParkesExecutive Officer, Director
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026BranchLab is an AI-native technology company focused on healthcare and pharmaceutical commercialization. Its platform, Pathwai, covers patient, healthcare professional (HCP), and caregiver audience exploration, agentic audience creation and optimization, omnichannel activation, and outcomes measurement, with the stated design goal of predicting health outcomes without exposing Protected Health Information (PHI). The company frames the industry problem as commercialization workflows that remain fragmented, manual, and offline because of privacy regulation, and positions predictive modeling on demographic and media-side signals as the replacement for claims-based or zero-party targeting.
The platform is used by pharmaceutical companies and their agencies to identify, activate, and optimize high-intent patient and HCP audiences in near real time. BranchLab reports an average increase of nearly 70% in marketing efficacy across a range of therapeutic areas. Alongside the core product, the company publishes research and informational resources, including a January 2026 study on predicting metabolic disease outcomes from demographic data and an August 2026 launch of state-by-state "Privacy Updates for Marketing Activation" tracking the fragmented US healthcare privacy landscape.
Leadership includes Josh Walsh (CEO), Michael Parkes (President & CRO), Dan Parkes (CTO), Kat Drake (VP of Data Science & AI), Vince Joralemon (Legal Counsel, Privacy and Policy), and Kellie Giangregorio (VP of Finance & HR).
Founding story
BranchLab states it was founded to close the gap between growing healthcare data availability and the ability to generate timely, actionable insight, addressing regulatory constraints, fragmented data systems, and manual workflows by designing intelligence systems that operate within regulation rather than around it.
Business model
BranchLab sells access to a software platform used by healthcare commercialization teams. Its stated buyer segments are pharmaceutical manufacturers (unifying research, marketing, and measurement), advertising agencies (activating audiences in-house), and publishers and platforms (activating proprietary audiences for qualified reach). The company describes an intended move toward a self-serve, agentic platform covering all commercialization workflows.
Traction
The platform is used by pharmaceutical companies and has delivered an average increase of nearly 70% in marketing efficacy across a diverse set of therapeutic areas. The company also cites 30x faster campaign execution, 3x higher audience quality than industry average versus claims-based targeting, 20x lower CPM versus competitive predictive audience targeting, and a 90% reduction in cost per target audience reached. Total funding reached $35 million following the May 2026 Series A, and dentsu integrated the platform in February 2026.
Latest developments
In May 2026 BranchLab announced a $26 million Series A led by McKesson Ventures, bringing total funding to $35 million, with proceeds earmarked for expanding enterprise deployments, deepening integrations across the healthcare and media ecosystem, and continued platform development. In August 2026 it launched Privacy Updates for Marketing Activation, a state-by-state legal resource on healthcare privacy for marketing activation. Earlier in 2026, dentsu integrated Pathwai, and BranchLab joined CIMM's inaugural startup program.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
BranchLab positions itself as an infrastructure layer for bringing therapies to market in the AI era, contrasting its predictive demographic modeling with claims-based and zero-party audience targeting approaches. Investors including McKesson Ventures, FCA Venture Partners, and Sanofi Ventures describe it as a potential core commercial intelligence layer for pharma. A dentsu Health SVP publicly characterized the approach as an advancement in healthcare marketing.
Technology
At the core of the platform is a transformer-based architecture that allows models to be trained on health data inside customer-controlled environments while deploying only non-sensitive demographic and media-side signals. This is used to predict health conditions and outcomes without relying on individual-level health information, and the company states it compresses commercialization workflows that previously took months into minutes. Product capabilities span audience exploration, AI-driven audience creation and optimization, omnichannel activation, and outcomes measurement under the Pathwai brand.
Go-to-market
BranchLab sells directly to pharmaceutical companies and works through their agencies, and pursues ecosystem integrations: dentsu integrated the Pathwai platform in February 2026 to turn data into healthcare audiences. Access to the platform is gated via a request-access flow on the company website. The company also uses published research, privacy-tracking resources, and industry program participation (CIMM's inaugural startup program) as market-facing activity.
Pharmaceutical manufacturers, healthcare advertising agencies, and publishers and platforms with proprietary healthcare audiences.
Geography
United States. Press materials for the Series A were datelined Boulder, Colorado, and the company is also described as operating from offices in New York, Colorado, and San Francisco.
Risks & controversies
The business depends on a fragmented and rapidly changing US healthcare privacy landscape, which BranchLab itself tracks on a state-by-state basis; its model relies on demographic and media-side signals as proxies for health conditions rather than protected health information. Performance figures such as the nearly 70% efficacy increase and the multiple-times comparisons against claims-based targeting are company-reported.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 2
by search overlap
Companies competing with BranchLab for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 5
launches, deals, and filingsBranchLab launched Privacy Updates for Marketing Activation, an informational resource providing state-by-state legal updates to help the industry track a fractured and rapidly changing healthcare privacy landscape.
BranchLab announced a $26 million Series A financing led by McKesson Ventures with participation from FCA Venture Partners, Sanofi Ventures, and AIX Ventures, bringing total funding to $35 million. Funds are to expand enterprise deployments, deepen healthcare and media ecosystem integrations, and continue building the unified AI platform for pharma commercialization.
$26M source ↗
dentsu integrated BranchLab's AI-native platform, Pathwai, to transform data into audiences for healthcare.
CIMM announced its inaugural startup program members, including BranchLab.
BranchLab published research finding that prediction of metabolic disease outcomes from demographic data improves when accounting for clinical heterogeneity.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 8
primary sources listed
- BranchLabbranchlab.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does BranchLab do?
- BranchLab builds an AI platform for pharma commercialization that models patient and HCP audiences without using individual-level health data.
- Who are BranchLab's investors?
- BranchLab's investors include AIX Ventures, FCA Venture Partners, McKesson Ventures, Next Ventures, NVP Capital, Sanofi Ventures, Swift Ventures, Newark Venture Partners and 1 more.
- How much funding has BranchLab raised?
- BranchLab has disclosed $28.8M raised across 1 of its 2 known rounds.
- Where is BranchLab headquartered?
- BranchLab is headquartered in New York, US.